| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 72,030 | 80,630 | 73,800 | 50,790 | 55,600 |
| Sales Growth | -10.67% | +9.25% | +45.30% | -8.65% | -20.01% |
| Net Income | 7,050 | 17,590 | 11,390 | -8,720 | 220 |
| Net Income Growth | -59.92% | +54.43% | +230.62% | -4,063.64% | -98.46% |
Dynavax Technologies (DVAX)
13.34 x 69 14.00 x 1
Post-market by (Cboe BZX)
13.58 -0.40 (-2.86%) 03/26/25 [NASDAQ]
13.34 x 69 14.00 x 1
Post-market 13.34 -0.24 (-1.77%) 17:57 ET
for Wed, Mar 26th, 2025
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Fiscal Year End Date: 12/31